Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences Inc (GILD) And Merck & Co Inc (MRK) Fighting For 3 Billion-Per-Quarter Profits

Gilead Sciences, Inc. (NASDAQ:GILD), AbbVie Inc (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have participated at the liver meeting in Boston, Massachusetts. Sovaldi is the $3 billion-per-quarter hepatitis C cure that allowed Gilead Sciences, Inc. (NASDAQ:GILD) take the lead in the market. The disease is expected to affect about 1 million Americans till 2020, according to CNBC.

Gilead Sciences, Inc. (NASDAQ:GILD)

“It affects as many as 180 million people worldwide and a lot of folks who have hepatitis C are heading towards what’s called cirrhosis. That’s liver damage, liver scarring which can lead to the need for a transplant after liver failure,” informed Meg Tirrell.

The current focus is on hepatitis B, as this health issue can be controlled by means of nowadays medicine, but it cannot be cured. Besides it, there are also some fatty liver conditions that can affect up to half of US’ population by 2030, which would explain why pharmaceuticals battle so fiercely to be the ones that pass the Phase I and Phase II trials. Merck & Co., Inc. (NYSE:MRK) is experimenting in reducing the current treatment period by combining different drugs that are already available, including those produced by Gilead Sciences, Inc. (NASDAQ:GILD).

“We did an experiment to look at 4 weeks, 6 weeks, and 8 weeks and, as it turns out, the 4 week duration might be a little too short, but it helped us a lot because we’re now focused around a box of 6 to 8 weeks. That’s much of an improvement compared with what’s currently available, which is 12 to 24 weeks” said Dr. Eliav Barr Merck Infectious Disease Vice President.

AbbVie Inc (NYSE:ABBV) is more like a spectator for the time being, but it might acquire the lead if it will manage to bypass Gilead Sciences, Inc. (NASDAQ:GILD)’s Sovaldi or if it will figure out a cure for hepatitis B, which seems an equally difficult task.

Disclosure: none
Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!